Guanfacine: all 66 studies that test it

Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Guanfacine and Cromolyn Sodium for POTS: The DBPOTS TrialNot yet recruitingNCT07757555Early Phase 1
• Treating Young Children With Attention Deficit Hyperactivity DisorderRecruitingNCT07300956Phase 4
• Guanfacine for Alcohol Use Disorder (AUD)RecruitingNCT06629259Phase 2
• ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in DepressionRecruitingNCT06408246Phase 2
• Guanfacine Extended-release for Adolescents With Cannabis UseRecruitingNCT05957848Phase 2
• Mechanistic Evaluation of Guanfacine on Drinking Behavior in Women and Men With Alcohol Use DisordersRecruitingNCT03764098Phase 2
• Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine StudyCompletedNCT04742673Phase 2Results posted
• The Effect of Guanfacine on Delirium in Critically Ill PatientsCompletedNCT04578886Phase 3Results posted
• The BIomarker Guided (BIG) Study for DepressionCompletedNCT04181736Phase 4Results posted
• A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)CompletedNCT04085172Phase 4Results posted
• Guanfacine to Improve Substance Use Outcomes in WomenCompletedNCT03980184Phase 2Results posted
• Efficacy of Guanfacine and Lidocaine Combination in Trigeminal Nerve Block for Pain Management in Trigeminal NeuropathyCompletedNCT03865940Phase 2Results posted
• Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)CompletedNCT03137082Phase 1/2Results posted
• Guanfacine for PONV and Pain After Sinus SurgeryCompletedNCT02882854Not applicableResults posted
• Treatment of OSA Associated Hypertension With Alpha 2 Agonist or DiureticCompletedNCT02699125Phase 4Results posted
• An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHDTerminatedNCT02259517Not applicableResults posted
• Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH)TerminatedNCT02192398Not applicableResults posted
• Does Guanfacine Attenuate Stress-Induced Drinking?CompletedNCT02164422Phase 2Results posted
• Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65).CompletedNCT02141113Phase 4Results posted
• Guanfacine Clinical Trial for Smoking CessationCompletedNCT02051309Phase 2Results posted
• Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive DisorderCompletedNCT02048241Phase 4Results posted
• PK/PD Comparison of Guanfacine ER and IRCompletedNCT01904526Phase 2Results posted
• Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With ADHDCompletedNCT01709695Phase 4Results posted
• Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and ToleranceTerminatedNCT01681264Phase 4Results posted
• The Effects of Ketamine and Guanfacine on Working Memory in Healthy SubjectsCompletedNCT01600885Not applicableResults posted
• Guanfacine in Children With Tic DisordersCompletedNCT01547000Phase 4Results posted
• Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in EuropeCompletedNCT01500694Phase 3Results posted
• SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)CompletedNCT01470469Phase 2Results posted
• Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis DependenceCompletedNCT01467999Phase 1Results posted
• Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedNCT01244490Phase 3Results posted
• Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental DisorderCompletedNCT01238575Phase 4Results posted
• Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated InsomniaTerminatedNCT01156051Phase 4Results posted
• Interventions for Children With Attention and Reading DisordersCompletedNCT01133847Phase 4Results posted
• Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HClCompletedNCT01081132Phase 3Results posted
• Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)CompletedNCT01069523Phase 4Results posted
• Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)CompletedNCT00997984Phase 3Results posted
• Guanfacine for the Treatment of Spatial Neglect and Impaired VigilanceCompletedNCT00955253Phase 2Results posted
• Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly SubjectsCompletedNCT00935493Not applicableResults posted
• A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy VolunteersCompletedNCT00919867Phase 1Results posted
• A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy VolunteersCompletedNCT00901576Phase 1Results posted
• Modeling Stress-precipitated Smoking Behavior for Medication DevelopmentCompletedNCT00773357Phase 2Results posted
• Efficacy and Safety of SPD503 in Combination With PsychostimulantsCompletedNCT00734578Phase 3Results posted
• Guanfacine Immediate-release Electrocardiogram Results (QTc) StudyCompletedNCT00672984Phase 1Results posted
• Stress and Medication Effects on Cocaine Cue ReactivityCompletedNCT00613015Phase 2Results posted
• Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity DisorderCompletedNCT00429273Phase 4Results posted
• SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional SymptomsCompletedNCT00367835Phase 3Results posted
• Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17CompletedNCT00152009Phase 3Results posted
• Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedNCT00151996Phase 2Results posted
• Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17CompletedNCT00150618Phase 3Results posted
• Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17CompletedNCT00150592Phase 2Results posted
• Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi SyndromeCompletedNCT05657860Phase 4
• Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi SyndromeWithdrawnNCT04066088Phase 4
• Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/HyperactivityCompletedNCT03662763Phase 3
• Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD AdolescentsCompletedNCT03333668Not applicable
• Guanfacine Extended Release and Mindfulness Skills TherapyWithdrawnNCT03258476Phase 4
• Noradrenergic Add-on Therapy With GuanfacineActive, not recruitingNCT03116126Phase 3
• CRT-Guanfacine for SPDCompletedNCT02524899Phase 2
• Inuniv and Working MemoryCompletedNCT01177306Phase 4
• Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (ADHD): Impact of Treatment With Sustained-release GuanfacineCompletedNCT01146002Phase 4
• Guanfacine to Reduce Stress-Induced Cocaine/Alcohol Craving and RelapseCompletedNCT00585754Phase 1
• Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in SchizophreniaStatus unknownNCT00469664Phase 4
• Guanfacine to Treat Borderline Personality DisorderStatus unknownNCT00358969Not applicable
• Pharmacology of Cognition in Schizotypal Personality DisorderTerminatedNCT00353379Phase 4
• Treatment of Supine Hypertension in Autonomic FailureCompletedNCT00223717Phase 1
• Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD)CompletedNCT00018603Phase 1
• Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity DisorderCompletedNCT00004376Phase 3

← Guanfacine overview